372 related articles for article (PubMed ID: 32097996)
1. Use of SGLT-2 Inhibitors in Patients with Type 2 Diabetes Mellitus and Abdominal Obesity: An Asian Perspective and Expert Recommendations.
Sheu WHH; Chan SP; Matawaran BJ; Deerochanawong C; Mithal A; Chan J; Suastika K; Khoo CM; Nguyen HM; Linong J; Luk A; Yoon KH
Diabetes Metab J; 2020 Feb; 44(1):11-32. PubMed ID: 32097996
[TBL] [Abstract][Full Text] [Related]
2. Impact of sodium glucose cotransporter 2 inhibitors on weight in patients with type 2 diabetes mellitus.
Barnett AH
Postgrad Med; 2013 Sep; 125(5):92-100. PubMed ID: 24113667
[TBL] [Abstract][Full Text] [Related]
3. Use of sodium-glucose co-transporter-2 inhibitors in patients with type 2 diabetes mellitus and multiple cardiovascular risk factors: An Asian perspective and expert recommendations.
Deerochanawong C; Chan SP; Matawaran BJ; Sheu WH; Chan J; Man NH; Suastika K; Khoo CM; Yoon KH; Luk A; Mithal A; Linong J
Diabetes Obes Metab; 2019 Nov; 21(11):2354-2367. PubMed ID: 31264765
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of SGLT-2i in overweight/obese, non-diabetic individuals: a meta-analysis of randomized controlled trials.
Shi Y; Si Y; Fu R; Zhang M; Jiang K; Dai W; Shen J; Li X; Yuan Y
Endokrynol Pol; 2022; 73(1):71-80. PubMed ID: 35119088
[TBL] [Abstract][Full Text] [Related]
5. Sodium-glucose co-transporter 2 inhibitors on weight change and cardiometabolic profiles in individuals with overweight or obesity and without diabetes: A meta-analysis.
Wong J; Chan KY; Lo K
Obes Rev; 2021 Dec; 22(12):e13336. PubMed ID: 34542222
[TBL] [Abstract][Full Text] [Related]
6. Use of sodium-glucose co-transporter-2 inhibitors in Asian patients with type 2 diabetes and kidney disease: An Asian perspective and expert recommendations.
Khoo CM; Deerochanawong C; Chan SP; Matawaran B; Sheu WH; Chan J; Mithal A; Luk A; Suastika K; Yoon KH; Ji L; Man NH; Pollock C
Diabetes Obes Metab; 2021 Feb; 23(2):299-317. PubMed ID: 33155749
[TBL] [Abstract][Full Text] [Related]
7. Rationale for the Early Use of Sodium-Glucose Cotransporter-2 Inhibitors in Patients with Type 2 Diabetes.
Handelsman Y
Adv Ther; 2019 Oct; 36(10):2567-2586. PubMed ID: 31444707
[TBL] [Abstract][Full Text] [Related]
8. 2019 Clinical Practice Guidelines for Type 2 Diabetes Mellitus in Korea.
Kim MK; Ko SH; Kim BY; Kang ES; Noh J; Kim SK; Park SO; Hur KY; Chon S; Moon MK; Kim NH; Kim SY; Rhee SY; Lee KW; Kim JH; Rhee EJ; Chun S; Yu SH; Kim DJ; Kwon HS; Park KS;
Diabetes Metab J; 2019 Aug; 43(4):398-406. PubMed ID: 31441247
[TBL] [Abstract][Full Text] [Related]
9. Effect of SGLT-2 inhibitors on body composition in patients with type 2 diabetes mellitus: A meta-analysis of randomized controlled trials.
Pan R; Zhang Y; Wang R; Xu Y; Ji H; Zhao Y
PLoS One; 2022; 17(12):e0279889. PubMed ID: 36584211
[TBL] [Abstract][Full Text] [Related]
10. How to fight obesity with antidiabetic drugs: targeting gut or kidney?
Baretić M; Troskot R
Minerva Endocrinol; 2015 Mar; 40(1):71-83. PubMed ID: 25366984
[TBL] [Abstract][Full Text] [Related]
11. Systematic review and meta-analysis for prevention of cardiovascular complications using GLP-1 receptor agonists and SGLT-2 inhibitors in obese diabetic patients.
Uneda K; Kawai Y; Yamada T; Kinguchi S; Azushima K; Kanaoka T; Toya Y; Wakui H; Tamura K
Sci Rep; 2021 May; 11(1):10166. PubMed ID: 33986377
[TBL] [Abstract][Full Text] [Related]
12. Cardiovascular Effects of New Oral Glucose-Lowering Agents: DPP-4 and SGLT-2 Inhibitors.
Scheen AJ
Circ Res; 2018 May; 122(10):1439-1459. PubMed ID: 29748368
[TBL] [Abstract][Full Text] [Related]
13. Management of Type 2 Diabetes in Frail Older Adults.
Bahat G; Ozkok S; Petrovic M
Drugs Aging; 2023 Sep; 40(9):751-761. PubMed ID: 37434085
[TBL] [Abstract][Full Text] [Related]
14. Prescribing sodium-glucose co-transporter-2 inhibitors for type 2 diabetes in primary care: influence of renal function and heart failure diagnosis.
Hinton W; Feher MD; Munro N; Joy M; de Lusignan S
Cardiovasc Diabetol; 2021 Jun; 20(1):130. PubMed ID: 34183018
[TBL] [Abstract][Full Text] [Related]
15. Ipragliflozin Improves Hepatic Steatosis in Obese Mice and Liver Dysfunction in Type 2 Diabetic Patients Irrespective of Body Weight Reduction.
Komiya C; Tsuchiya K; Shiba K; Miyachi Y; Furuke S; Shimazu N; Yamaguchi S; Kanno K; Ogawa Y
PLoS One; 2016; 11(3):e0151511. PubMed ID: 26977813
[TBL] [Abstract][Full Text] [Related]
16. Sodium-glucose cotransporter 2 inhibitors: an evidence-based practice approach to their use in the natural history of type 2 diabetes.
Schwartz SS; Ahmed I
Curr Med Res Opin; 2016 May; 32(5):907-19. PubMed ID: 26854518
[TBL] [Abstract][Full Text] [Related]
17. Combating the dual burden: therapeutic targeting of common pathways in obesity and type 2 diabetes.
Scheen AJ; Van Gaal LF
Lancet Diabetes Endocrinol; 2014 Nov; 2(11):911-22. PubMed ID: 24731666
[TBL] [Abstract][Full Text] [Related]
18. Metabolic effects of SGLT-2 inhibitors beyond increased glucosuria: A review of the clinical evidence.
Scheen AJ; Paquot N
Diabetes Metab; 2014 Dec; 40(6 Suppl 1):S4-S11. PubMed ID: 25554070
[TBL] [Abstract][Full Text] [Related]
19. Sodium-Glucose Cotransporter-2 (SGLT-2) Inhibitors and the Treatment of Type 2 Diabetes.
Kramer CK; Zinman B
Annu Rev Med; 2019 Jan; 70():323-334. PubMed ID: 30256723
[TBL] [Abstract][Full Text] [Related]
20. Glycemic efficacy and safety of glucagon-like peptide-1 receptor agonist on top of sodium-glucose co-transporter-2 inhibitor treatment compared to sodium-glucose co-transporter-2 inhibitor alone: A systematic review and meta-analysis of randomized controlled trials.
Patoulias D; Stavropoulos K; Imprialos K; Katsimardou A; Kalogirou MS; Koutsampasopoulos K; Zografou I; Papadopoulos C; Karagiannis A; Doumas M
Diabetes Res Clin Pract; 2019 Dec; 158():107927. PubMed ID: 31733280
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
